Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma

Edoardo Giannini, Paola Romagnoli, Alberto Fasoli, Federica Botta, Domenico Risso, Roberto Testa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Hepatitis C virus infection-related cirrhosis is a major risk factor for the development of hepatocellular carcinoma. Hepatocellular carcinoma in anti-hepatitis C virus positive cirrhotics shows an increasing prevalence with ageing, although it is not clear whether the age of the patients can be considered a critical factor in the overall assessment of severity of disease or in the choice of therapeutic procedures and prognosis. Objective: To evaluate the influence of older age on modality of presentation, therapeutic choices, outcome, and survival in anti-hepatitis C virus patients with hepatocellular carcinoma. Methods: We retrospectively evaluated 75 anti-hepatitis C virus positive cirrhotic patients with hepatocellular carcinoma consecutively referred to our unit. Patients were sub-divided into two sub-groups according to their age (<65 or ≥ 65 years) at tumor diagnosis. The characteristics of the patients and of hepatocellular carcinoma, therapeutic procedures, and survival were then analyzed. Results: Median age of the patients was 68 years and mean duration of infection was 24 years. Clinical characteristics of older hepatocellular carcinoma patients were no different from those of younger ones. Hepatocellular carcinoma was more frequently of diffuse type in patients aged <65 years. However, therapeutic options were no different between the two sub-groups of patients, and a similar proportion of patients did not undergo therapy in either group. Overall, 1- and 2-year survival rates were 73% and 51%, respectively. After a mean follow-up of 21 months a higher number of patients aged

Original languageEnglish
Pages (from-to)457-462
Number of pages6
JournalAge and Ageing
Volume31
Issue number6
DOIs
Publication statusPublished - Nov 2002

Fingerprint

Hepatocellular Carcinoma
Hepacivirus
Therapeutics
Survival
Virus Diseases
Fibrosis
Survival Rate
Infection

Keywords

  • Age
  • Cirrhosis
  • CLIP score
  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Prognosis
  • Therapy

ASJC Scopus subject areas

  • Ageing

Cite this

Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. / Giannini, Edoardo; Romagnoli, Paola; Fasoli, Alberto; Botta, Federica; Risso, Domenico; Testa, Roberto.

In: Age and Ageing, Vol. 31, No. 6, 11.2002, p. 457-462.

Research output: Contribution to journalArticle

@article{ee9a6752081d4745a89ff410abe2d2a7,
title = "Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma",
abstract = "Background: Hepatitis C virus infection-related cirrhosis is a major risk factor for the development of hepatocellular carcinoma. Hepatocellular carcinoma in anti-hepatitis C virus positive cirrhotics shows an increasing prevalence with ageing, although it is not clear whether the age of the patients can be considered a critical factor in the overall assessment of severity of disease or in the choice of therapeutic procedures and prognosis. Objective: To evaluate the influence of older age on modality of presentation, therapeutic choices, outcome, and survival in anti-hepatitis C virus patients with hepatocellular carcinoma. Methods: We retrospectively evaluated 75 anti-hepatitis C virus positive cirrhotic patients with hepatocellular carcinoma consecutively referred to our unit. Patients were sub-divided into two sub-groups according to their age (<65 or ≥ 65 years) at tumor diagnosis. The characteristics of the patients and of hepatocellular carcinoma, therapeutic procedures, and survival were then analyzed. Results: Median age of the patients was 68 years and mean duration of infection was 24 years. Clinical characteristics of older hepatocellular carcinoma patients were no different from those of younger ones. Hepatocellular carcinoma was more frequently of diffuse type in patients aged <65 years. However, therapeutic options were no different between the two sub-groups of patients, and a similar proportion of patients did not undergo therapy in either group. Overall, 1- and 2-year survival rates were 73{\%} and 51{\%}, respectively. After a mean follow-up of 21 months a higher number of patients aged",
keywords = "Age, Cirrhosis, CLIP score, Hepatitis C virus, Hepatocellular carcinoma, Prognosis, Therapy",
author = "Edoardo Giannini and Paola Romagnoli and Alberto Fasoli and Federica Botta and Domenico Risso and Roberto Testa",
year = "2002",
month = "11",
doi = "10.1093/ageing/31.6.457",
language = "English",
volume = "31",
pages = "457--462",
journal = "Age and Ageing",
issn = "0002-0729",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma

AU - Giannini, Edoardo

AU - Romagnoli, Paola

AU - Fasoli, Alberto

AU - Botta, Federica

AU - Risso, Domenico

AU - Testa, Roberto

PY - 2002/11

Y1 - 2002/11

N2 - Background: Hepatitis C virus infection-related cirrhosis is a major risk factor for the development of hepatocellular carcinoma. Hepatocellular carcinoma in anti-hepatitis C virus positive cirrhotics shows an increasing prevalence with ageing, although it is not clear whether the age of the patients can be considered a critical factor in the overall assessment of severity of disease or in the choice of therapeutic procedures and prognosis. Objective: To evaluate the influence of older age on modality of presentation, therapeutic choices, outcome, and survival in anti-hepatitis C virus patients with hepatocellular carcinoma. Methods: We retrospectively evaluated 75 anti-hepatitis C virus positive cirrhotic patients with hepatocellular carcinoma consecutively referred to our unit. Patients were sub-divided into two sub-groups according to their age (<65 or ≥ 65 years) at tumor diagnosis. The characteristics of the patients and of hepatocellular carcinoma, therapeutic procedures, and survival were then analyzed. Results: Median age of the patients was 68 years and mean duration of infection was 24 years. Clinical characteristics of older hepatocellular carcinoma patients were no different from those of younger ones. Hepatocellular carcinoma was more frequently of diffuse type in patients aged <65 years. However, therapeutic options were no different between the two sub-groups of patients, and a similar proportion of patients did not undergo therapy in either group. Overall, 1- and 2-year survival rates were 73% and 51%, respectively. After a mean follow-up of 21 months a higher number of patients aged

AB - Background: Hepatitis C virus infection-related cirrhosis is a major risk factor for the development of hepatocellular carcinoma. Hepatocellular carcinoma in anti-hepatitis C virus positive cirrhotics shows an increasing prevalence with ageing, although it is not clear whether the age of the patients can be considered a critical factor in the overall assessment of severity of disease or in the choice of therapeutic procedures and prognosis. Objective: To evaluate the influence of older age on modality of presentation, therapeutic choices, outcome, and survival in anti-hepatitis C virus patients with hepatocellular carcinoma. Methods: We retrospectively evaluated 75 anti-hepatitis C virus positive cirrhotic patients with hepatocellular carcinoma consecutively referred to our unit. Patients were sub-divided into two sub-groups according to their age (<65 or ≥ 65 years) at tumor diagnosis. The characteristics of the patients and of hepatocellular carcinoma, therapeutic procedures, and survival were then analyzed. Results: Median age of the patients was 68 years and mean duration of infection was 24 years. Clinical characteristics of older hepatocellular carcinoma patients were no different from those of younger ones. Hepatocellular carcinoma was more frequently of diffuse type in patients aged <65 years. However, therapeutic options were no different between the two sub-groups of patients, and a similar proportion of patients did not undergo therapy in either group. Overall, 1- and 2-year survival rates were 73% and 51%, respectively. After a mean follow-up of 21 months a higher number of patients aged

KW - Age

KW - Cirrhosis

KW - CLIP score

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Prognosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0036862977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036862977&partnerID=8YFLogxK

U2 - 10.1093/ageing/31.6.457

DO - 10.1093/ageing/31.6.457

M3 - Article

C2 - 12446292

AN - SCOPUS:0036862977

VL - 31

SP - 457

EP - 462

JO - Age and Ageing

JF - Age and Ageing

SN - 0002-0729

IS - 6

ER -